Check patentability & draft patents in minutes with Patsnap Eureka AI!

Tumor neoantigen epitope peptide Pep1 and polymer and application thereof

A technology of antigenic epitopes and multimers, which is applied in the fields of molecular biology and immunology, and can solve problems such as difficult identification of epitope peptides

Pending Publication Date: 2022-03-01
BEIJING IMMUPEUTICS MEDICINE TECH LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0022] Difficulties in identification of KRASpG12D-specific T cells: it is difficult to determine the immunogenic epitope peptide, and the diversity of T cells that recognize antigens is strong (multiple T in one person, multiple T in many people)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor neoantigen epitope peptide Pep1 and polymer and application thereof
  • Tumor neoantigen epitope peptide Pep1 and polymer and application thereof
  • Tumor neoantigen epitope peptide Pep1 and polymer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1 Prediction, screening and verification of antigenic peptides

[0071]The discovery of antigenic epitope peptide is the key to prepare peptide-MHC tetramer. The epitope peptide with higher affinity to MHC and higher immunity to stimulate immune response is used to prepare the preferred polypeptide of the polypeptide-MHC tetramer that recognizes the antigen-specific T cells. In the present invention, high-affinity and high-immunogenicity epitope peptides are screened, and the process for preparing pMHC is as follows image 3 Shown:

[0072] Using the self-developed antigen epitope prediction algorithm (patent publication number CN112002374A), predict the neoantigen epitope for the mutation sites that occur frequently in tumors (KRASpG12D, KRASpG12V, KRASpG12R, KRASpG12C, Tp53pR249S, TP53pR175H, etc.), and obtain candidate A total of 40 candidate high-affinity epitope peptides were obtained by screening the affinity scores of the predicted epitope peptides and ...

Embodiment 2

[0082] Embodiment 2 Tetramer preparation

[0083] 1. pMHC preparation and peptide replacement

[0084] This part uses the existing pMHC monomer preparation method (patent publication number CN109293779A, CN106397549A) to prepare the sensitive peptide pMHC carrying biotin, wherein the sequence of the sensitive peptide is: KILGFVFJV (HLA-A0201 type, where J refers to 3-amino-3 -(2nitro)phenylpropanoic acid). With the prepared sensitive peptide p sense -MHC-based, the target peptide pMHC was prepared by incubating with the target peptide (CMV-derived antigen peptide) after 366nm ultraviolet irradiation, and the pMHC was captured on the ELISA plate by incubating with the ELISA plate coated with β2M antibody, and then the parent Hodin-HRP combines avidin with biotin attached to the heavy chain of MHCα3, and finally adds HRP substrate to reflect the content of pMHC through the absorbance value, which in turn can reflect the detachment degree of sensitive peptide after ultraviolet ...

Embodiment 3

[0121] Example 3 Tetramer activity evaluation

[0122] In this part, the Tetramer prepared by the self-made CMV-derived antigen peptide of the present invention and the commercialized similar CMV-derived antigen active product were stained on the same batch of DC-CTL, and the two sets of data were compared to evaluate the targeting activity of the self-made Tetramer. After being verified, use one of the previously screened peptides (the amino acid sequence of the present invention is the tumor neoantigen epitope peptide Pep1 shown in SEQ ID NO.4) to prepare respective corresponding Tetramers, and then stimulate the prepared Tetramers with these antigenic peptides respectively. Staining on DC-CTL was used to evaluate the activity of Tetramer prepared by this peptide and the specificity of DC-CTL after preparation. The specific operation steps are as follows:

[0123] Reagents, consumables, materials and equipment

[0124] Reagents: PBS buffer (pH7.4), Peptide sample, p sense...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of molecular biology and immunology, and particularly relates to a tumor neoantigen epitope peptide Pep1 and a polymer and application thereof. The amino acid sequence of the tumor neoantigen epitope peptide Pep1 disclosed by the invention is as shown in SEQ ID NO. 4; or the amino acid sequence of the tumor neoantigen epitope peptide has more than 90% similarity with the sequence shown in SEQ ID NO.4 through amino acid substitution, deletion or increase; or the amino acid sequence of the tumor neoantigen epitope peptide comprises a sequence shown as SEQ ID NO.4 or comprises a sequence which is 90% or more similar to the sequence shown as SEQ ID NO.4 through amino acid replacement, deletion or increase. The antigen peptide of the polymer disclosed by the invention is a tumor neoantigen epitope peptide Pep1. According to the invention, on one hand, a thought is provided for clinical adoptive cancer immunotherapy, and on the other hand, a detection means is provided for drug research and development, so that the drug research and development can be better served, and effective therapeutic drugs can serve cancer patients as soon as possible.

Description

technical field [0001] The invention belongs to the fields of molecular biology and immunology, and particularly relates to a tumor neoantigen epitope peptide Pep1 and its multimer and application. Background technique [0002] The existing identification and analysis of immune cells in this field mainly include the following categories of technologies: [0003] Enzyme-linked immunosorbent spot (Elispot) analysis [0004] Such as figure 1 As shown, the well plate of Elispot has been coated with a cytokine-specific primary antibody, and the antigen added by exogenous sources is presented to the target T cells by the presenting cells in the well plate of Elispot. After incubation, specific T cells can produce effector cytokines by recognizing the corresponding specific antigens, and the cytokines can be detected in the form of spots after being captured by the coated antibody. Elispot assays can therefore provide information on the frequency of immune responses to specific ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47G01N33/574G01N33/543
CPCC07K14/4748G01N33/57438G01N33/543
Inventor 宋瑾张强韩英沈宁张恒辉
Owner BEIJING IMMUPEUTICS MEDICINE TECH LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com